ÂÜŔňÂŇÂ×

Prior to founding Vida Ventures, Stefan was an investment professional at Third Rock Ventures, an early-stage life sciences venture capital firm. At Third Rock, he was part of the founding team of Decibel Therapeutics, a hearing-focused drug discovery and development platform company.

Before Third Rock, Stefan was an investor at TPG Capital, where he focused on majority, control stakes in healthcare companies. Stefan worked on a variety of equity and debt financings, including Aptalis Pharma and Biomet. Prior to TPG, Stefan was an investment banker at Credit Suisse’s healthcare banking group.

Stefan received his B.S. with Honors in Biological Sciences at Stanford University. He completed his M.S. in Biology at Stanford, where he conducted biomedical research in the lab of Dr. Helen Blau at Stanford Medical School. Stefan later received his MBA from Harvard Business School. Stefan currently serves on the Board of Directors for Praxis Precision Medicines (“PRAX”). He was previously a Board Director or Observer at Kyverna Therapeutics, Oyster Point Therapeutics (“OYST”), Dyne Therapeutics (“DYN”), Sutro Biopharma (“STRO”).